AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NEKTAR THERAPEUTICS Director's Dealing 2021

Sep 25, 2021

32134_dirs_2021-09-24_02511b63-1a31-4f3d-8bcd-532cb7ab891b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2021-09-22

Reporting Person: GREER R SCOTT (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-22	Common Stock	A	10200	$0.00	Acquired	280874	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-22	Stock Option	$17.78	A	20400	Acquired	2029-09-21	Common Stock (20400)	Direct

Footnotes

F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of the Issuer's common stock.

F2: This RSU award vests in full, one year following September 22, 2021.

F3: This stock option vests in equal monthly installments over the one-year period beginning on September 22, 2021.